Novartis dealt another setback to broader Menveo use

Novartis ($NVS) hit another snag in its quest to broaden use of the meningococcal vaccine Menveo. The FDA has asked for more information on Menveo use in infants, delaying the company's ability to market the shot for that group. The setback could hobble Menveo as it seeks to compete with Sanofi's ($SNY) Menactra, an analyst told Dow Jones. Report